WallStreetZenWallStreetZen

NASDAQ: CDXC
Chromadex Corp Stock

$2.88+0.25 (+9.51%)
Updated Jul 11, 2024
CDXC Price
$2.88
Fair Value Price
N/A
Market Cap
$217.55M
52 Week Low
$1.25
52 Week High
$4.65
P/E
-57.6x
P/B
7.51x
P/S
3.15x
PEG
N/A
Dividend Yield
N/A
Revenue
$83.17M
Earnings
-$3.53M
Gross Margin
61%
Operating Margin
-4.16%
Profit Margin
-4.2%
Debt to Equity
0.87
Operating Cash Flow
$5M
Beta
0.92
Next Earnings
Aug 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A

CDXC Overview

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and IMMULINA, a Braun-type lipoproteins, including spirulina extracts and active compounds, which are used to support human immune function. It also offers analytical reference standards and services comprising supply of products to conduct quality control of raw materials and consumer products in dietary supplements, cosmetics, food and beverages, life sciences, and pharmaceutical industries. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation is headquartered in Los Angeles, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CDXC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

CDXC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CDXC is poor value based on its book value relative to its share price (7.51x), compared to the US Biotechnology industry average (6.37x)
P/B vs Industry Valuation
CDXC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CDXC due diligence checks available for Premium users.

Be the first to know about important CDXC news, forecast changes, insider trades & much more!

CDXC News

Valuation

CDXC fair value

Fair Value of CDXC stock based on Discounted Cash Flow (DCF)
Price
$2.88
Fair Value
-$3.56
Undervalued by
180.92%
CDXC is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

CDXC price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-57.6x
Industry
-14.46x
Market
31.84x

CDXC price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
7.51x
Industry
6.37x
CDXC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

CDXC's financial health

Profit margin

Revenue
$22.2M
Net Income
-$492.0k
Profit Margin
-2.2%
CDXC's Earnings (EBIT) of -$3.46M... subscribe to Premium to read more.
Interest Coverage Financials
CDXC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$54.1M
Liabilities
$25.1M
Debt to equity
0.87
CDXC's short-term assets ($48.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CDXC's short-term assets ($48.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CDXC's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CDXC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$295.0k
Investing
-$41.0k
Financing
-$14.0k
CDXC's operating cash flow ($4.62M)... subscribe to Premium to read more.
Debt Coverage Financials

CDXC vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
CDXC$217.55M+9.51%-57.60x7.51x
PRLD$218.07M+10.58%-2.11x1.03x
ALDX$216.27M+7.06%-7.14x1.91x
GNFT$219.47M+0.94%-6.99x2.97x
ATNM$219.80M+4.38%-4.32x5.01x

Chromadex Stock FAQ

What is Chromadex's quote symbol?

(NASDAQ: CDXC) Chromadex trades on the NASDAQ under the ticker symbol CDXC. Chromadex stock quotes can also be displayed as NASDAQ: CDXC.

If you're new to stock investing, here's how to buy Chromadex stock.

What is the 52 week high and low for Chromadex (NASDAQ: CDXC)?

(NASDAQ: CDXC) Chromadex's 52-week high was $4.65, and its 52-week low was $1.25. It is currently -38.06% from its 52-week high and 130.4% from its 52-week low.

How much is Chromadex stock worth today?

(NASDAQ: CDXC) Chromadex currently has 75,538,787 outstanding shares. With Chromadex stock trading at $2.88 per share, the total value of Chromadex stock (market capitalization) is $217.55M.

Chromadex stock was originally listed at a price of $11.70 in Jun 25, 2008. If you had invested in Chromadex stock at $11.70, your return over the last 16 years would have been -75.38%, for an annualized return of -8.39% (not including any dividends or dividend reinvestments).

How much is Chromadex's stock price per share?

(NASDAQ: CDXC) Chromadex stock price per share is $2.88 today (as of Jul 11, 2024).

What is Chromadex's Market Cap?

(NASDAQ: CDXC) Chromadex's market cap is $217.55M, as of Jul 12, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Chromadex's market cap is calculated by multiplying CDXC's current stock price of $2.88 by CDXC's total outstanding shares of 75,538,787.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.